TCBPY (TC BioPharm (Holdings)) DeferredTaxAndRevenue: $0.00 Mil (As of Dec. 2024)


What is TC BioPharm (Holdings) DeferredTaxAndRevenue?

TC BioPharm (Holdings) TCBPY DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2024.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

TC BioPharm (Holdings)'s current deferred tax and revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

TC BioPharm (Holdings) DeferredTaxAndRevenue Related Terms

TC BioPharm (Holdings) DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for TC BioPharm (Holdings)'s DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TC BioPharm (Holdings) DeferredTaxAndRevenue Chart

TC BioPharm (Holdings) Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial 2.66 2.63 0.00 0.00 0.00

TC BioPharm (Holdings) Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $0.00 Mil mean?
TC BioPharm (Holdings) (TCBPY) has a DeferredTaxAndRevenue of $0.00 Mil as of Dec. 2024. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on TC BioPharm (Holdings).
Is TC BioPharm (Holdings)'s DeferredTaxAndRevenue too high?
TC BioPharm (Holdings)'s current DeferredTaxAndRevenue is $0.00 Mil.
How does TC BioPharm (Holdings)'s DeferredTaxAndRevenue compare to SIGY and CNBX?
TC BioPharm (Holdings)'s DeferredTaxAndRevenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on TC BioPharm (Holdings). TC BioPharm (Holdings)'s current DeferredTaxAndRevenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TC BioPharm (Holdings) stock overvalued right now?
TC BioPharm (Holdings) (TCBPY) has a current DeferredTaxAndRevenue of $0.00 Mil. The current DeferredTaxAndRevenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For TC BioPharm (Holdings) (TCBPY), the current DeferredTaxAndRevenue is $0.00 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TC BioPharm (Holdings) Business Description

Address Maxim 1, 2 Parklands Way, Holytown, Motherwell, Scotland, GBR, ML1 4WR
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.